Alvotech, Polifarma ink pact to sell potential Eylea biosimilar in Turkey
Zorica Nastasic         
Alvotech (NASDAQ:ALVO) signed an exclusive agreement with Polifarma Ilac San. ve tic. for the commercialization in Turkey of AVT06, a proposed biosimilar toÂ Regeneron Pharmaceuticals (REGN) andÂ Bayer's (OTCPK:BAYRY) (OTCPK:BAYZF) EyleaÂ (aflibercept).
Under the agreement,Â Polifarma will handleÂ market registration and commercialization of AVT06 in Turkey, while Alvotech will be responsible for developing and manufacturing the therapy.
Alvotech noted thatÂ AVT06 is currently in clinical development. In July 2022, Alvotech said it started a patient study to evaluate AVT06 and Eylea in adult patients with neovascular (wet) age-related macular degeneration (AMD).